about
PPARγ as a Novel Therapeutic Target in Lung CancerPPARγ in Bacterial Infections: A Friend or Foe?Nitrated fatty acids reverse pulmonary fibrosis by dedifferentiating myofibroblasts and promoting collagen uptake by alveolar macrophages.Nitrated Fatty Acids Reverse Cigarette Smoke-Induced Alveolar Macrophage Activation and Inhibit Protease Activity via Electrophilic S-Alkylation.Murine model of allergen induced asthma.Effects of JAM-A deficiency or blocking antibodies on neutrophil migration and lung injury in a murine model of ALIDown-regulated peroxisome proliferator-activated receptor γ (PPARγ) in lung epithelial cells promotes a PPARγ agonist-reversible proinflammatory phenotype in chronic obstructive pulmonary disease (COPD).PPAR Agonists for the Prevention and Treatment of Lung Cancer.Emerging pharmaceutical therapies for COPD.Transforming growth factor β suppresses peroxisome proliferator-activated receptor γ expression via both SMAD binding and novel TGF-β inhibitory elements.Endothelial cell peroxisome proliferator-activated receptor γ reduces endotoxemic pulmonary inflammation and injury.PPARs: Key Regulators of Airway Inflammation and Potential Therapeutic Targets in Asthma.The nitrated fatty acid 10-nitro-oleate attenuates allergic airway disease.Nur77: Key Functions and Therapeutic Prospects in Inflammation-Related Lung DiseasesIdentification and Molecular Characterization of PPARδ as a Novel Target for Covalent Modification by 15-deoxy-Δ-prostaglandin JAirway Epithelial Cell Peroxisome Proliferator-Activated Receptor γ Regulates Inflammation and Mucin Expression in Allergic Airway DiseaseRole of GPx3 in PPARγ-induced protection against COPD-associated oxidative stressMolecular, chemical, and structural characterization of prostaglandin A2 as a novel agonist for Nur77
P50
Q28068114-22DB6322-0A29-4959-BA53-FD92C2D26417Q28070173-97A1875E-6A84-4E44-979B-825491577D80Q34512881-FF9A3F0A-D1AD-40D3-B5F3-BE0FFE6F5FD8Q36000626-26DF9209-F1AA-4751-BF3A-EFA24DCA0AAAQ36305310-87AEF2D7-112B-4991-A2CB-5D5DFB8BFED3Q36454409-9A29792C-24ED-4C97-8199-04B0EBD6DAF4Q37622525-7BAB18F5-1FB3-43C5-9297-26D0A419D722Q37681630-77FEF61D-8F38-4996-9696-71BAE0D90955Q38645203-763DD54E-92FE-4EE0-BFED-6D341F806DFBQ38720663-56112977-AD46-490F-A450-0872C5923111Q41600866-AA687688-E84F-4D10-BA82-69425071D30BQ49953684-2D30EF85-F46A-4A0F-873F-3CA46F80CB15Q53095793-ED271EAA-48F2-48E9-BA6B-9E23195C68FFQ58591873-547C192D-48D6-432D-925A-B434786D5C6AQ58603870-65024E38-B26A-4801-9B98-D068E1C8FD8AQ90644701-EF0D4011-497C-4AD6-A552-4DA82F68EA8CQ91005160-6AF82E1E-BE90-4A14-9852-15F87E2FCA3BQ93161092-0AD765DE-E71F-475A-BCD2-1CD372A05DA2
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sowmya P Lakshmi
@ast
Sowmya P Lakshmi
@en
Sowmya P Lakshmi
@es
Sowmya P Lakshmi
@nl
type
label
Sowmya P Lakshmi
@ast
Sowmya P Lakshmi
@en
Sowmya P Lakshmi
@es
Sowmya P Lakshmi
@nl
prefLabel
Sowmya P Lakshmi
@ast
Sowmya P Lakshmi
@en
Sowmya P Lakshmi
@es
Sowmya P Lakshmi
@nl
P106
P31
P496
0000-0003-1708-9462